Technical Analysis for KMPH - KemPharm, Inc.

Grade Last Price % Change Price Change
grade F 1.49 12.03% 0.16
KMPH closed up 12.03 percent on Monday, May 20, 2019, on 77 percent of normal volume.
1 Watcher
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Up
See historical KMPH trend table...

Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Crossed Above 20 DMA Bullish 0.00%
Wide Bands Range Expansion 0.00%
1,2,3 Retracement Bearish Bearish Swing Setup 12.03%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 12.03%
Earnings Movers Other 12.03%
Inside Day Range Contraction 12.03%
Wide Bands Range Expansion 12.03%
1,2,3 Retracement Bearish Bearish Swing Setup 12.03%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 12.03%

Older signals for KMPH ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Track My Stocks
Configure default chart indicators
Basic chart:

Profile
KemPharm is a specialty pharmaceutical company focused on the discovery and development of NME prodrugs to treat serious medical conditions through its Ligand Activated Therapy (LAT) platform technology. KemPharm utilizes its LAT platform technology to generate improved prodrug versions of FDA-approved drugs in the high needs areas of pain, ADHD and other CNS disorders.
Health Pharmaceutical Pharmaceutical Industry Pain Medication FDA Pharmacokinetics Platform Technology Attention Deficit Hyperactivity Disorder Adhd Amphetamine Methylphenidate
Is KMPH a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
May 14 KemPharm misses by $0.04
May 14 KemPharm Reports First Quarter 2019 Results
May 8 The Daily Biotech Pulse: Daiichi's Positive Breast Cancer Trial, Supernus Slumps, Axovant Reverse Split
May 3 The Daily Biotech Pulse: Obseva Reports Positive Endometriosis Drug Trial, Assembly Biosciences Execs Depart, Coherus Settles With Amgen
May 2 The Daily Biotech Pulse: FDA Nod For Sanofi's Dengue Vaccine, Veracyte Offering, Biogen Reports Positive Data
Apr 20 FDA OKs first non-drug treatment for ADHD
Apr 12 DIS, APC among premarket gainers
Apr 12 The Daily Biotech Pulse: Merck's Keytruda Clinches Another FDA Win, KemPharm Close To NDA Filing For ADHD Drug
Apr 11 KemPharm up 15% after hours as KP415 NDA nears finish line
Apr 11 KemPharm Completes KP415 Pre-NDA Meeting with FDA
See more KMPH news...
Indicators
Indicator Value
52 Week High 7.15
52 Week Low 1.15
Average Volume 221,067
200-Day Moving Average 2.7476
50-Day Moving Average 1.6587
20-Day Moving Average 1.3963
10-Day Moving Average 1.296
Average True Range 0.126
ADX 28.69
+DI 18.323
-DI 20.8799
Chandelier Exit (Long, 3 ATRs ) 1.372
Chandelier Exit (Short, 3 ATRs ) 1.528
Upper Bollinger Band 1.6911
Lower Bollinger Band 1.1015
Percent B (%b) 0.66
BandWidth 42.225883
MACD Line -0.1
MACD Signal Line -0.1276
MACD Histogram 0.0276
Fundamentals Value
Market Cap 21.84 Million
Num Shares 14.7 Million
EPS -3.10
Price-to-Earnings (P/E) Ratio -0.48
Price-to-Sales 0.00
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.78
Resistance 3 (R3) 1.75 1.62 1.73
Resistance 2 (R2) 1.62 1.55 1.64 1.71
Resistance 1 (R1) 1.56 1.51 1.59 1.59 1.70
Pivot Point 1.43 1.43 1.45 1.45 1.43
Support 1 (S1) 1.37 1.36 1.40 1.40 1.28
Support 2 (S2) 1.24 1.32 1.26 1.27
Support 3 (S3) 1.18 1.24 1.25
Support 4 (S4) 1.21